Report Summary: Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizing Competitive Assessment & Data Disclosure Summaries

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Chemical; Manufacturing; Consumer Products; Consulting; Medical Device; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Zydus; King Pharmaceuticals; Genentech; Mallinckrodt; Bayer Healthcare; Merck; Lac Mac; Merck Serono; Alembic; Novo Nordisk; Lilly; Pfizer; Boehringer Ingelheim; Pharma Consulting; actavis; ProStrakan; Cadila Pharmaceuticals; Quintiles; Amgen; Ranbaxy; Daiichi Sankyo; Roche; Rxperts; Sanofi; Shire; Vivus

Study Snapshot

This study engaged 30 executives from 27 leading pharmaceutical, biotech, and life sciences companies. Twelve research participants represented large pharma organizations, while the remaining benchmark class emerged from mid-sized and smaller companies.

Deep-dive interviews were conducted with senior bio-pharma leaders with experience on Boards of Directors and in the roles of Chief Executive, Chief Marketing Officer, Chief Medical Officer, and Head of Competitive and Business Intelligence.

Key Findings

Use 5 Pages or Fewer for Competitive Landscape Assessments: Very concise executive briefs work best for presenting market landscape summaries to different leadership groups. More than half of benchmark partners use 5 pages or fewer for presentations to all groups. Competitive assessments to Investor Relations groups are often the most concise presentation type, while those to Executive Committees may run longer.